View in EDS

Vascular dysfunctions during radiation retinopathy.

Saved in:
Bibliographic Details
Title: Vascular dysfunctions during radiation retinopathy.
Authors: Niaudet, Colin1 (AUTHOR), Mathis, Thibaud2,3 (AUTHOR), Pham, Thao-Nguyen4 (AUTHOR), Quintyn, Jean-Claude5 (AUTHOR), Paris, François1,6 (AUTHOR) francois.paris@inserm.fr, Thariat, Juliette1,4 (AUTHOR) j.thariat@baclesse.unicancer.fr
Source: Radiotherapy & Oncology. Jan2026, Vol. 214, pN.PAG-N.PAG. 1p.
Subjects: Ocular tumors, Retinal diseases, Computer-assisted image analysis (Medicine), Vision disorders, Microcirculation disorders, Endothelium diseases, Therapeutics
Abstract: • Radiation retinopathy is a disabling complication from radiotherapy potentially causing blindness. • The prevalence of radiation retinopathy varies between 6 % and 40 % depending on tumor. • Early endothelial dysfunctions are precursors of functional deterioration. • Radiation retinopathy manifests as a late-onset, occlusive vascular pathology. • Mitigating early neurovascular dysfunction could prevent radiation retinopathy. Optic tissue toxicity remains a major limitation of radiation therapy for ocular, brain, skull base, and head and neck tumors. Among the most frequent complications, radiation retinopathy (RR) occurs in 6% of patients treated for extraocular tumors and in more than 40% of those with ocular tumors. After an initial asymptomatic stage characterized by vascular remodeling and chronic retinal ischemia, RR may progress to irreversible vision loss and significantly impaired quality of life. Advances in non-invasive, high-resolution imaging have improved our understanding of the molecular and cellular mechanisms underlying RR in both preclinical and clinical models. In particular, multimodal imaging—and especially optical coherence tomography angiography (OCTA)—has enabled earlier detection of RR in humans. Animal studies have highlighted vascular obstruction and rarefaction, together with early neurovascular dysfunction, as central features of the clinical phase. Beyond preventive measures such as dose constraints, biological and imaging biomarkers may help guide targeted interventions. In this review, we summarize current evidence on the sequential endothelial and neuronal alterations that drive RR and discuss molecular and cellular pathways that could inform the development of potential therapeutic strategies. [ABSTRACT FROM AUTHOR]
Copyright of Radiotherapy & Oncology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:• Radiation retinopathy is a disabling complication from radiotherapy potentially causing blindness. • The prevalence of radiation retinopathy varies between 6 % and 40 % depending on tumor. • Early endothelial dysfunctions are precursors of functional deterioration. • Radiation retinopathy manifests as a late-onset, occlusive vascular pathology. • Mitigating early neurovascular dysfunction could prevent radiation retinopathy. Optic tissue toxicity remains a major limitation of radiation therapy for ocular, brain, skull base, and head and neck tumors. Among the most frequent complications, radiation retinopathy (RR) occurs in 6% of patients treated for extraocular tumors and in more than 40% of those with ocular tumors. After an initial asymptomatic stage characterized by vascular remodeling and chronic retinal ischemia, RR may progress to irreversible vision loss and significantly impaired quality of life. Advances in non-invasive, high-resolution imaging have improved our understanding of the molecular and cellular mechanisms underlying RR in both preclinical and clinical models. In particular, multimodal imaging—and especially optical coherence tomography angiography (OCTA)—has enabled earlier detection of RR in humans. Animal studies have highlighted vascular obstruction and rarefaction, together with early neurovascular dysfunction, as central features of the clinical phase. Beyond preventive measures such as dose constraints, biological and imaging biomarkers may help guide targeted interventions. In this review, we summarize current evidence on the sequential endothelial and neuronal alterations that drive RR and discuss molecular and cellular pathways that could inform the development of potential therapeutic strategies. [ABSTRACT FROM AUTHOR]
ISSN:01678140
DOI:10.1016/j.radonc.2025.111294